Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination chemotherapy regimen consisting of clofarabine and cyclophosphamide. This combination demonstrates synergistic antileukemic effects, primarily used for treating relapsed or refractory acute leukemias in pediatric patients. Clofarabine inhibits DNA polymerase \u03b1 and ribonucleotide reductase, disrupts mitochondrial membrane integrity leading to programmed cell death, and inhibits DNA repair. Cyclophosphamide is an alkylating agent that cross-links DNA via active metabolites. The combination shows enhanced efficacy because clofarabine potentiates cyclophosphamide's activity by inhibiting the repair of cyclophosphamide-induced DNA damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clofarabine + cyclophosphamide.